Result card

  • EFF5a: Are IVIG effective in improving activities of daily living of patients with mild-to-moderate Alzheimer’s disease when compared to placebo or acetyl cholinesterase inhibitors?
  • EFF5b: Are IVIG effective in improving activities of daily living of patients with moderate-to-severe Alzheimer’s disease when compared to placebo or memantine? Jump to
English

Are IVIG effective in improving activities of daily living of patients with mild-to-moderate Alzheimer’s disease when compared to placebo or acetyl cholinesterase inhibitors?

Authors: Luca Vignatelli, Luciana Ballini, Susanna Maltoni, Jelena Barbaric, Mirjana Huic, Pernilla Östlund.

Internal reviewers: Gerardo Atienza, Agnes Mannik

The same methodology was used as described in section for the whole domain.

Data on activity of daily living changes, measured by ADCS-ADL (co-primary outcome), were available from 301 patients (out of 383) of one RCT {NCT00818662}. See Appendix 2 for details.

Mean score change from baseline at 18 months in ADCS-ADL did not differ between IVIG 400 mg/kg group (104 patients) and placebo group (95 patients) (0.4, 95% CI -2.9 to 3.7; P = 0.812) and between IVIG 200 mg/kg group (102 patients) and placebo group (95 patients) (-0.9, 95% CI -4.3 to 2.5; P = 0.602). Accordingly mean score change from baseline at 9 months in in ADCS-ADL did not differ between IVIG 400 mg/kg group and placebo group and between IVIG 200 mg/kg group and placebo group.

Table 4. Summary of findings: activity of daily living changes in patients with mild-to-moderate AD treated with IVIG

Activities of daily living: ADCS-ADL mean score change from baseline to 18 months

0.4 (95% CI -2.9 to 3.7); P = 0.812

-0.9 (95% CI -4.3 to 2.5); P = 0.602

Very low

 

Critical
Completely
Vignatelli L et al. Result Card EFF5a In: Vignatelli L et al. Clinical Effectiveness In: Jefferson T, Cerbo M, Vicari N [eds.]. Use of Intravenous immunoglobulins for Alzeheimer’s disease including Mild Cognitive Impairment [Core HTA], Agenas - Agenzia nazionale per i servizi sanitari regionali ; 2015. [cited 30 October 2020]. Available from: http://corehta.info/ViewCover.aspx?id=267

Are IVIG effective in improving activities of daily living of patients with moderate-to-severe Alzheimer’s disease when compared to placebo or memantine?

Authors: Luca Vignatelli, Luciana Ballini, Susanna Maltoni, Jelena Barbaric, Mirjana Huic, Pernilla Östlund.

Internal reviewers: Gerardo Atienza, Agnes Mannik

The same methodology was used as described in section for the whole domain.

No evidence is available on effectiveness of IVIG for patients with moderate-to-severe AD.

Critical
Completely
Vignatelli L et al. Result Card EFF5b In: Vignatelli L et al. Clinical Effectiveness In: Jefferson T, Cerbo M, Vicari N [eds.]. Use of Intravenous immunoglobulins for Alzeheimer’s disease including Mild Cognitive Impairment [Core HTA], Agenas - Agenzia nazionale per i servizi sanitari regionali ; 2015. [cited 30 October 2020]. Available from: http://corehta.info/ViewCover.aspx?id=267

References